Skyland Analytics announced the appointment of James C. Mullen to Skyland's Advisory Board.
"Jim Mullen has unique experience in the industry having previously served as CEO of a leading contract manufacturer, and as CEO of a leading innovator in biotechnology," said Robert DiScipio, CEO of Skyland Analytics. "Jim's perspective on the vital role that process data management plays in enabling compliance with FDA guidelines for data integrity, Continued Process Verification and partner management will enhance Skyland's capability to continue to deliver Part-11 compliant software for drug developers and manufacturers."
Mullen was most recently the CEO of Patheon, a contract developer/manufacturers of pharmaceuticals. Previously, he served 10 years as CEO and President of Biogen. His 30-year career includes extensive experience in pharmaceutical and biotech manufacturing, engineering, sales, marketing, mergers and acquisitions. His experience includes biotechnology, pharmaceuticals and specialty chemicals. He holds a Bachelor of Science in Chemical Engineering from Rensselaer Polytechnic Institute, and a Master of Business Administration from Villanova University.